Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID) (NCT06924021)
🩺 Plain-English Summary (8th-Grade Level)
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Who can join: Review the eligibility criteria below.
Location: Bergstrom Eye Research LLC — Fargo, North Dakota
Age range: 50 Years
🧪 Interventions in This Study
- Retinal Imaging (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Bergstrom Eye Research LLC — Fargo, North Dakota
- Erie Retina Research — Erie, Pennsylvania
- Retina Foundation of the Southwest — Dallas, Texas
- Valley Retina Institute — McAllen, Texas
- Retina Consultants of Texas (Houston) — The Woodlands, Texas
- University of Utah - John A. Moran Eye Center — Salt Lake City, Utah
- University Station Eye Care Clinic — Madison, Wisconsin
- Charles Research Center — Buenos Aires,
- Adelaide Eye and Retina Centre — Adelaide,
- Centre Hospialier Intercommunal de Paradis (Centre Monticelli Paradis) — Marseille,
- University of Bonn - Department of Ophthalmology — Bonn,
- Sankara Nethralaya, Medical Research Foundation — Chennai, Tamil Nadu
- Aravind Eye Hospital — Chennai, Tamil Nadu
- Aga Khan University — Karachi,
📞 Contact the Study Coordinator
Phone: (608) 262-1334
Email: wrc.support@wisc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Age-Related Macular Degeneration
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders — Springfield, Illinois
- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration — San Francisco, California
- ForeseeHome NRich Registry — Toms River, New Jersey
- Impact of Non-Exudative Type 1 MNV on AMD Progression — Salt Lake City, Utah
- A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration — Phoenix, Arizona
- Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration — Scottsdale, Arizona
Explore by condition: All Age-Related Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.